24 Mar 2026 · to Health
specific steps being taken to ensure the HSE considers the time-critical nature of Friedreich’s ataxia during the current price negotiations for skyclarys; and the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims
24 Mar 2026 · to Health
Deputy Jennifer Whitmore asked the Minister for Health whether she will consider funding the medication skyclarys for people living with Friedreich’s ataxia; and if she will make a statement on the matter. [22147/26
24 Mar 2026 · to Health
Muirí asked the Minister for Health if she will intervene to ensure that the HSE prioritises the conclusion of reimbursement negotiations for skyclarys, given that it is currently the only available treatment for Friedreich’s ataxia and is identified as addressing an unmet need under the National Rare
19 Mar 2026 · to Health
Deputy John Clendennen asked the Minister for Health for an update on the accessibility of Omaveloxolone (brand name Skyclarys) for the treatment of Friedreich’s ataxia; and if she will make a statement on the matter. [21312/26
18 Mar 2026 · to Health
Deputy John Brady asked the Minister for Health for an update on the application for reimbursement for the drug Skyclarys (omaveloxalone); and if she will make a statement on the matter. [18485/26
18 Mar 2026 · to Health
Deputy Pádraig Mac Lochlainn asked the Minister for Health the current status of the assessment, pricing negotiations and potential reimbursement approval for Skyclarys (omaveloxolone) for the treatment of Friedreich's Ataxia (FA) in Ireland; when patients can expect a decision on access to this medicine
18 Mar 2026 · to Health
steps being taken to ensure the HSE considers the "time-critical" nature of Friedreich's Ataxia during the current price negotiations for Skyclarys; the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement, which aims
18 Mar 2026 · to Health
Deputy Rose Conway-Walsh asked the Minister for Health when she expects an outcome from the application for pricing and reimbursement of omaveloxolone (Skyclarys) for the treatment of Friedreich’s Ataxia in adults and adolescents aged 16 years and older; if not yet known, the efforts that will
18 Mar 2026 · to Health
specific steps being taken to ensure the HSE recognises the time-critical nature of Friedreich’s Ataxia during the current price negotiations for Skyclarys; how the commitments in the National Rare Disease Strategy 2025–2030 and the 2026 IPHA Framework Agreement are being applied to this case
18 Mar 2026 · to Health
Deputy Seán Canney asked the Minister for Health when the drug Skyclarys will be reimbursed for patients with Friedreich’s Ataxia (details supplied); and if she will make a statement on the matter. [18731/26
18 Mar 2026 · to Health
Deputy Albert Dolan asked the Minister for Health the status of the HSE and Department of Health assessment of Omaveloxolone (Skyclarys) for the treatment of Friedreich’s Ataxia; the timeline for completing the reimbursement process; the engagement that has taken place with patient representatives and clinical experts
18 Mar 2026 · to Health
that the time-critical nature of Friedreich’s Ataxia is fully recognised and reflected in the ongoing price negotiations for the reimbursement of Skyclarys; and if she will make a statement on the matter. [18745/26
18 Mar 2026 · to Health
Strategy 2025–2030, particularly regarding timely access to approved therapies for rare disease patients, are being applied to the current reimbursement process for Skyclarys for the treatment of Friedreich’s Ataxia; and if she will make a statement on the matter. [18746/26
18 Mar 2026 · to Health
which the 180-day decision timeline contained within the 2026 IPHA Framework Agreement is being implemented in the case of Skyclarys, given that over 570 days have now elapsed since the reimbursement application was submitted; and if she will make a statement on the matter. [18747/26
18 Mar 2026 · to Health
Deputy Louis O'Hara asked the Minister for Health if the drug Skyclarys (omaveloxolone), used for the treatment of Friedreich’s ataxia, will be made available under licence in Ireland; and if she will make a statement on the matter. [18769/26
18 Mar 2026 · to Health
that are being taken to ensure the HSE recognises the time-critical nature of Friedreich’s ataxia during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [18770/26
18 Mar 2026 · to Health
reimbursement decision timeline mandated under the Health (Pricing and Supply of Medical Goods) Act 2013 was applied to the drug skyclarys (omaveloxolone); and if she will make a statement on the matter. [18771/26
18 Mar 2026 · to Health
Deputy Sorca Clarke asked the Minister for Health to outline the current status of the reimbursement application for skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia; if she will provide a detailed update of ongoing engagement between the HSE and the manufacturer; and the way in which
18 Mar 2026 · to Health
IPHA Framework Agreement 2026, including the stated 180-day decision target for reimbursement applications are being adhered to in the case of skyclarys, given that more than 570 days have elapsed since the initial application was submitted in August 2024. [18961/26
18 Mar 2026 · to Health
ensure that the HSE recognises and responds to the time-critical nature of Friedreich’s ataxia during the current price negotiations for skyclarys; the way in which the commitments, which are outlined in the National Rare Disease Strategy 2025–2030, and the 2026 IPHA Framework Agreement (which aims
18 Mar 2026 · to Health
Deputy Paul Lawless asked the Minister for Health the measures in place to ensure HSE price talks for skyclarys take account for Friedreich’s ataxia time-sensitive progression. [19311/26
18 Mar 2026 · to Health
which the National Rare Disease Strategy 2025–2030 and 2026 IPHA Framework Agreement, especially the 180-day timeline, applies to the negotiations for skyclarys; and to resolve this urgent unmet need without further postponement. [19312/26
18 Mar 2026 · to Health
March 2026, the position regarding a timeline for the completion of the assessment of the proposal for reimbursement of Skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19446/26
18 Mar 2026 · to Health
Ward asked the Minister for Health if any submissions can be consider as part of the assessment of the proposal for reimbursement of Skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19447/26
18 Mar 2026 · to Health
Ward asked the Minister for Health if she will facilitate a meeting with the campaign group that are seeking State funded reimbursement of skyclarys for patients with Friedreich’s ataxia; and if she will make a statement on the matter. [19448/26